Parker Waichman LLP

Eli Lilly Abandons Development of New Cholesterol Drug

Eli Lilly Ceased Work For New Cholesterol Drug. Drug maker Eli Lilly announced that it was ceasing work on a new cholesterol-lowering drug, after the drug failed to perform well in a phase 3 clinical trial. The drug, evacetrapib, was designed to prevent heart attacks and other cardiovascular problems by modifying cholesterol levels, the Wall […]

Cholesterol Drug

Eli Lilly Ceased Work For New Cholesterol Drug. Drug maker Eli Lilly announced that it was ceasing work on a new cholesterol-lowering drug, after the drug failed to perform well in a phase 3 clinical trial.

The drug, evacetrapib, was designed to prevent heart attacks and other cardiovascular problems by modifying cholesterol levels, the Wall Street Journal reports.

Interim results from a large clinical trial showed that evacetrapib was not likely to significantly reduce cardiovascular risk compared to a placebo, despite having the desired cholesterol-lowering effect. Lilly said the decision to halt the trial was not based on safety findings, according to the WSJ.

Evacetrapib is one of new class of drugs—cholesterol esterase transfer protein (CETP) inhibitors. CETP inhibitors are designed to lower LDL (“bad”) cholesterol. Thus far, Medscape reports, this class of drugs has had disappointing results for the drug makers.

Previous CETP inhibitors torcetrapib and dalcetrapib

Previous CETP inhibitors torcetrapib and dalcetrapib were both pulled from the pipeline. In a large trial, torcetrapib showed an increased risk of mortality and cardiovascular events and dalcetrapib failed to show a benefit.

A phase 3 trial is the third of four phases in Food and Drug Administration (FDA) drug approval: the drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

ACCELERATE, a phase-3 randomized trial for evacetrapib, had enrolled 12,095 patients in 37 countries with diabetes, a history of acute coronary syndrome, statin-resistant dyslipidemia, and other high-risk features.

The study followed the patients for the composite end point of CV death, heart attack, stroke, revascularization (stent or catheterization), or hospitalization for unstable angina. Medscape reports that the trial was scheduled to continue for another year, but the safety monitoring board recommended that it be stopped based on a prespecified data review that “suggested there was a low probability the study would achieve its primary end point based on results to date,” according to a statement from Lilly.

Lilly’s stock plummeted after the announcement, the WSJ reports

Lilly’s stock plummeted after the announcement, the WSJ reports. Until the announcement, Lilly has been showing signs of recovering from a series of patent expirations that significantly decreased sales of older medicines like Zyprexa and Cymbalta for mental illnesses.

Once a patent expires, other drug makers can enter the market with a generic version of the drug, eating into sales and bringing down the price of the brand name drug.

Since the beginning of 2014, Lilly has won regulatory approval to market three new drugs, and several experimental treatments under development look promising. This helped move Lilly’s shares to a 10-year high last month, but Monday’s evacetrapib announcement caused shares to drop by 7.8 percent.

Lilly is awaiting regulatory decisions on potential new drugs for lung cancer and psoriasis, and it is involved in late-stage studies of drugs for arthritis and breast cancer.

Lilly has avoided the megamergers undertaken by some of its rivals. The company’s chief executive, John Lechleiter, said he feels big mergers in the past disrupted research efforts. But for a smaller company, the failure of even one drug can have a big impact of the company’s financial outlook.

And the WSJ points out that larger drug makers have the advantage of a cushion Lilly does not have when difficulties arise in their research and development efforts.

Need Legal Help Regarding Cholesterol Drug?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529)

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness , Value I am so thankful for the service I received from PW LLP. I would also like to give a shoutout to Benita. She kept me informed in regard to my case.
Helen Washington
3 years ago
5 Star Reviews 150
I have been working for the last 3 years with Tina Morace of Parker Waichman LLP to date and happy to say she handled my case from start to finish diligently. Never had any doubt about her professionalism. If i had questions i knew who to call that is Tina Morace. If i needed an answer she was prompt in delivering her reply and moreso never hesitated in getting in touch with me at all times to let me know how my case is doing. It was a pleasure working with Tina Morace. A very pleasant person to talk to and i would not hesitate to recommend any person who wishes to have their case handled by her. Tina Morace is an asset to Parker Waichman LLP and am proud of her expertise, knowledge and her responsive service of which am proud of her . Thank you Tina Morace for all your help and continued service with Parker Waichman LLP.
Monica Libert
2 years ago
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness
Thomas Caragliano
3 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038